Meta-analysis shows intensive blood pressure control fails to reduce all-cause mortality in patients with type 2 diabetes, suggesting limited impact on cardiovascular events.
Background: There is no evidence from randomized trials to support a standard strategy of lowering systolic blood pressure below 140 mm Hg in persons with type 2 diabetes mellitus. We investigated whether intensive therapy targeting normal systolic pressure (i.e., <120 mm Hg) reduces major cardiovascular events in participants with type 2 diabetes at high risk for cardiovascular events. Methods: We systematically searched PubMed, Embase and Cochrane databases for randomized controlled trials (RCTs) comparing the impact of intensive versus standard blood pressure control in patients with type 2 diabetes mellitus with the primary outcome of interest being all-cause mortality. We pooled risk ratio and their 95% confidence intervals (CIs). We also examined heterogeneity using I 2 statistics and studies with high heterogeneity were examined using the random-effect model. Results: We included 8 RCTs consisting of 23,121 patients with type 2 diabetes mellitus of which 11,926 (51.6%) had intensive blood pressure treatment while 11,195 (48.4%) had standard blood pressure treatment. The mean age of the included studies was 59.6 years and 56.6% were males. There were no significant differences between groups for all-cause mortality (RR = 0.91; 95% CI [0.82, 1.02]; I 2 = 17.8%; p = 0.104; Figure 1), cardiovascular death (RR = 0.87; 95% CI [0.62, 1.23]; I 2 = 35.6%; p = 0.427), heart failure (RR = 0.84; 95% CI [0.70, 1.00]; I 2 = 0%; p = 0.045) and myocardial infarction (RR = 0.75; 95% CI [0.55, 1.03]; I 2 = 57.1%; p = 0.077). However, intensive blood pressure control significantly reduced the incidence of stroke (RR = 0.56; 95% CI [0.41, 0.75]; I 2 = 64.3%; p < 0.001) compared to standard treatment. Conclusions: Intensive blood pressure control did not reduce all-cause mortality, cardiovascular death, heart failure and myocardial infarction despite reducing the incidence of stroke.
No takes yet. Share an insight, caveat, or question.
Ogunmola et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: